Khurram Jamil Appointed Chief Medical Officer at Galectin Therapeutics

Khurram Jamil, M.D., a senior executive with knowledge in liver disease, has been named Chief Medical Officer of Galectin Therapeutics. With over 20 years of expertise in the hepatology field, Jamil joined the firm in March 2024 as Vice President Clinical Development and Medical Director. He oversaw the conduct of the NAVIGATE clinical study for belapectin. Several clinical studies he conducted and oversaw were approved as new medications in the US and other nations.

Joel Lewis, CEO of Galectin Therapeutics, stated that he is confident in Jamil's ability to lead and that he is looking forward to the Interim Analysis results in December 2024. Citing the increasing unmet medical need for MASH cirrhosis and the possibility of belapectin as a treatment for these patients, Dr. Jamil emphasised his honour and commitment to spearheading the belapectin initiative. Dr. Pol Boudes, who is no longer with the firm, will be succeeded by Dr. Jamil. Galectin Therapeutics expresses gratitude to Dr. Boudes for his assistance and best wishes for his further undertakings.